Table 1.
| Parameters‖ |
CYP3A5*3/*6/*7 metabolic composite
|
P-values† | |||
|---|---|---|---|---|---|
| Extensive | Intermediate | Poor | |||
| No. of Patients, n (%) | 8.0 (12) | 24 (36) | 35 (52) | – | |
| Study dose (mg) | 5.7 (1.5) | 3.9 (1.7) | 2.5 (1.1) | (Ext vs Poor) *** (Int vs Poor) ** |
|
| Race | African-American, n (%) | 8.0 (100) | 21 (88) | 6.0 (17) | *** |
| White, n (%) | 0.0 (0.0) | 3.0 (12) | 29 (83) | ||
| Sex | Male, n (%) | 4.0 (50) | 15 (63) | 19 (54) | ns |
| Female, n (%) | 4.0 (50) | 9.0 (37) | 16 (46) | ||
| Age (years) | 46 (8.3) | 49 (11) | 50 (13) | ns | |
| Total body weight (kg) | 89 (22) | 90 (21) | 85 (19) | ns | |
| Body mass index (kg/m2) | 31 (6.2) | 30 (6.8) | 30 (5.5) | ns | |
| Albumin (g/dL) | 4.1 (0.3) | 4.1 (0.2) | 4.1 (0.3) | ns | |
| Glucose (mg/dL) | 92 (19) | 122 (77) | 115 (69) | ns | |
| Triglycerides (mg/dL) | 134 (39) | 125 (67) | 154 (157) | ns | |
| Total Cholesterol (mg/dL) | 158 (24) | 150 (26) | 161 (51) | ns | |
| HDL (mg/dL) | 46 (14) | 52 (15) | 50 (19) | ns | |
| LDL (mg/dL) | 86 (21) | 74 (22) | 81 (32) | ns | |
| eGFR (mL/min/1.73m2) | 46 (14) | 54 (17) | 58 (14) | ns | |
| Serum creatinine (mg/dL) | 1.9 (0.6) | 1.6 (0.4) | 1.3 (0.3) | (Ext vs Poor)** (Int vs Poor) ** |
|
| Hemoglobin (g/dL) | 12 (1.2) | 12 (1.4) | 12 (1.4) | ns | |
| Hematocrit (%) | 37 (3.8) | 38 (4.7) | 38 (3.6) | ns | |
| Platelet (cells/mm3) | 231 (67) | 195 (59) | 196 (46) | ns | |
| Leukocytes (cells/mm3) | 5.7 (1.9) | 4.9 (1.6) | 5.4 (2.1) | ns | |
| ABCB1 1236T>C | CC, n (%) | 4.0 (50) | 11 (46) | 14 (40) | ns |
| CT, n (%) | 4.0 (50) | 7.0 (29) | 14 (40) | ||
| TT, n (%) | 0.0 (0.0) | 6.0 (25) | 7.0 (20) | ||
| ABCB1 2677T>G,A | GG, n (%) | 7.0 (88) | 17 (71) | 13 (37) | * |
| GT, n (%) | 1.0 (12) | 5.0 (21) | 15 (43) | ||
| TT, n (%) | 0.0 (0.0) | 2.0 (8.2) | 7.0 (20) | ||
| ABCB1 3435T>C CC, n (%) | 4.0 (50) | 13 (54) | 13 (37) | ns | |
| CT, n (%) | 4.0 (50) | 9.0 (38) | 15 (43) | ||
| TT, n (%) | 0.0 (0.0) | 2.0 (8.0) | 7.0 (20) | ||
| Time post-transplant (years) | 2.3 (1.8) | 3.4 (1.9) | 2.9 (3.0) | ns | |
| Diabete presence, n (%) | 2.0 (25) | 11 (46) | 12 (34) | ns | |
| ACEI use, n (%) | 1.0 (13) | 10 (42) | 9.0 (26) | ns | |
| ARB use, n (%) | 1.0 (13) | 3.0 (13) | 4.0 (11) | ns | |
| BB use, n (%) | 7.0 (88) | 21 (88) | 22 (63) | ns | |
| CCB use, n (%) | 6.0 (75) | 18 (79) | 20 (49) | * | |
| Prednisone use, n (%) | 2.0 (25) | 7.0 (29) | 5.0 (14) | ns | |
| Statin use, n (%) | 1.0 (13) | 10 (42) | 12 (34) | ns | |
‖
Data represented as mean (standard deviation) or frequency (percentage)
HDL High-density lipoprotein, LDL Low-density lipoprotein, eGFR Glomerular filtration rate 47, ACEI Angiotensin converting enzyme inhibitor, ARB Angiotensin receptor blocker, BB Beta-blocker, CCB Calcium-channel blocker
†
P-value is based on χ2 test for categorical variables, and on Kruskal-Wallis test (Dunn’s multiple comparison test) for continuous variables. ns: non-significant,
*
p-value < 0.05,
**
p-value < 0.01,
***
p-value < 0.001.